Predicting Success with a First-Generation Hybrid Closed-Loop Artificial Pancreas System Among Children, Adolescents, and Young Adults with Type 1 Diabetes: A Model Development and Validation Study

التفاصيل البيبلوغرافية
العنوان: Predicting Success with a First-Generation Hybrid Closed-Loop Artificial Pancreas System Among Children, Adolescents, and Young Adults with Type 1 Diabetes: A Model Development and Validation Study
المؤلفون: Laura Pyle, Tim Vigers, Cari Berget, Darrell M. Wilson, Laurel H. Messer, Rayhan A. Lal, Gregory P. Forlenza, Bruce A. Buckingham, R. Paul Wadwa, Korey K. Hood, Marina Basina, David M. Maahs, Kimberly A. Driscoll
المصدر: Diabetes Technol Ther
سنة النشر: 2023
مصطلحات موضوعية: Insulin pump, Blood Glucose, Pancreas, Artificial, medicine.medical_specialty, Adolescent, Endocrinology, Diabetes and Metabolism, Logistic regression, Artificial pancreas, External validity, Young Adult, Endocrinology, Insulin Infusion Systems, medicine, Humans, Hypoglycemic Agents, Insulin, Child, Glycemic, Type 1 diabetes, business.industry, Model selection, Blood Glucose Self-Monitoring, Area under the curve, Original Articles, medicine.disease, Medical Laboratory Technology, Diabetes Mellitus, Type 1, Physical therapy, business
الوصف: Background Hybrid Closed Loop (HCL) systems aid individuals with type 1 diabetes in improving glycemic control, however, sustained use over time has not been consistent for all users. This study developed and validated prognostic models for successful 12-month use of the first commercial HCL system based on baseline and 1-month or 3-month data. Methods and materials Data from participants at the Barbara Davis Center (N=85) who began use of the MiniMed 670G HCL were used to develop prognostic models using logistic regression and Lasso model selection. Candidate factors included sex, age, duration of diabetes, baseline HbA1c, race, ethnicity, insurance status, history of insulin pump and continuous glucose monitor use, 1-month or 3-month Auto Mode use, boluses per day, and time in range (70-180 mg/dL; TIR), and scores on behavioral questionnaires. Successful use of HCL was predefined as Auto Mode use ≥60%. The 3-month model was then externally validated against a sample from Stanford University (N=55). Results Factors in the final model included baseline HbA1c, sex, ethnicity, 1-month or 3-month Auto Mode use, Boluses per Day, and TIR. The 1-month and 3-month prognostic models had very good predictive ability with area under the curve values of 0.894 and 0.900, respectively. External validity was acceptable with an area under the curve of 0.717. Conclusions Our prognostic models use clinically accessible baseline and early device-use factors to identify risk for failure to succeed with 670G HCL technology. These models may be useful to develop targeted interventions to promote success with new technologies.
تدمد: 1557-8593
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ea0861287a120c1e0b2328ec5cc6946Test
https://pubmed.ncbi.nlm.nih.gov/34780306Test
حقوق: OPEN
رقم الانضمام: edsair.doi.dedup.....5ea0861287a120c1e0b2328ec5cc6946
قاعدة البيانات: OpenAIRE